Publications
Detailed Information
The effect of gene therapy using CTLA4Ig/silica-nanoparticles on canine experimental autoimmune thyroiditis
Cited 9 time in
Web of Science
Cited 11 time in Scopus
- Authors
- Issue Date
- 2008-05-02
- Publisher
- Wiley-Blackwell
- Citation
- J Gene Med 2008; 10: 795-804
- Keywords
- autoimmune thyroiditis ; CTLA4Ig ; cytokine ; dog ; semi-quantitative ; RT-PCR ; T cell proliferation
- Abstract
- Background The present study aimed to determine the effect of canine
CTLA4Ig on canine autoimmune thyroiditis. In a previous study, we
established a canine model of autoimmune thyroiditis by immunizing normal
dogs with bovine thyroglobulin. An in vitro study using recombinant CTLA4Ig
revealed that this protein can inhibit the expression of Th1-type cytokines
and the pro-inflammatory cytokines tested.
Methods As a result of the in vitro study, we constructed therapeutic
CTLA4Ig/silica-nanoparticles and applied them to the treatment of
experimentally induced canine autoimmune thyroiditis.
Results Gene therapy resulted in significant reductions in anti-caninethyroglobulin
autoantibody titer, anti-T4 antibody titer and T-cell proliferation
against thyroglobulin and in the mRNA expressions of interleukin-18
in fresh peripheral blood mononuclear cells (PBMC) from all dogs. There was
also a significant reduction compared to day 0 in tumor necrosis factor-α and
interferon-γ levels in the supernatant from cultured PBMC.
Conclusions The CTLA4Ig-induced suppression of Th1 cytokines is
relatively more significant than it appears because autoimmune thyroiditis is a
Th1-polarized disease. Thus, CTLA4Ig can improve Th1/Th2 cytokine balance
in autoimmune thyroiditis by downregulating Th1 cytokines.
- ISSN
- 1099-498X
- Language
- English
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.